Cargando…

Onabotulinum Toxin A (Botox®) in the Treatment of Neurogenic Bladder Overactivity

Botulinum toxin (BT) is a potent presynaptic neuromuscular blocking agent which induces selective, reversible muscle weakness for months when injected intramuscularly. During recent years BT has revolutionized the treatment of previously intractable symptoms of detrusor overactivity. Based on a syst...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rohrsted, Malene, Nordsten, Cecilie Bagi, Bagi, Per
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Kowsar 2012
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3614280/ https://www.ncbi.nlm.nih.gov/pubmed/23573462 http://dx.doi.org/10.5812/numonthly.1864

Ejemplares similares

Treatment of neurogenic detrusor overactivity and overactive bladder with Botox (onabotulinumtoxinA): Development, insights, and impact
por: Nitti, Victor, et al.
Publicado: (2023)

Intradetrusor Injections of Onabotulinum Toxin-A in Children With Urinary Incontinence due to Neurogenic Detrusor Overactivity Refractory to Antimuscarinic Treatment
por: Tarcan, Tufan, et al.
Publicado: (2014)

Outcomes of Intradetrusor Onabotulinum Toxin A Therapy in Overactive Bladder Refractory to Sacral Neuromodulation
por: Trinh, Hamilton, et al.
Publicado: (2019)

Onabotulinum toxin-A (Botox) for spastic equinus in cerebral palsy: a prospective kinematic study
por: Hastings-Ison, T., et al.
Publicado: (2018)

Patients profiling for Botox® (onabotulinum toxin A) treatment for migraine: a look at white matter lesions in the MRI as a potential marker
por: Bumb, Anja, et al.
Publicado: (2013)

Efficacy of Onabotulinum Toxin A (Botox) versus Abobotulinum Toxin A (Dysport) Using a Conversion Factor (1 : 2.5) in Treatment of Primary Palmar Hyperhidrosis
por: El Kahky, Hanan Mohamed, et al.
Publicado: (2013)

Onabotulinum Toxin A Intradetrusor Injections in Children with Neurogenic Lower Urinary Tract Dysfunction: Long-Term Histological Effects on the Bladder Wall
por: Pellegrino, Chiara, et al.
Publicado: (2023)

Botulinum Toxin in Neurogenic Detrusor Overactivity
por: D'Ancona, Carlos Arturo Levi, et al.
Publicado: (2012)

Heart-Rate Variability Correlates to Choroidal Thickness in Central Serous Chorioretinopathy
por: Nordsten, Cecilie Bagi, et al.
Publicado: (2023)

Cost-Utility Analysis of Oxybutynin vs. OnabotulinumtoxinA (Botox) in the Treatment of Overactive Bladder Syndrome
por: Shabir, Habiba, et al.
Publicado: (2021)

Onabotulinum toxin A in the treatment of chronic migraine: patient selection and special considerations
por: Barbanti, Piero, et al.
Publicado: (2017)

Botulinum toxin A for the Treatment of Overactive Bladder
por: Hsieh, Po-Fan, et al.
Publicado: (2016)

Pharmacokinetics of solifenacin in pediatric populations with overactive bladder or neurogenic detrusor overactivity
por: Tannenbaum, Stacey, et al.
Publicado: (2020)

Prospective randomized trial of 100u vs 200u botox in the treatment of idiopathic overactive bladder
por: AlTaweel, Waleed, et al.
Publicado: (2011)

Cost-Effectiveness Analysis of OnabotulinumtoxinA (BOTOX(®)) for the Management of Urinary Incontinence in Adults with Neurogenic Detrusor Overactivity: A UK Perspective
por: Hamid, Rizwan, et al.
Publicado: (2014)

In Patients with Neurogenic Detrusor Overactivity and Hinman’s Syndrome: Would Intravesical Botox Injections Decrease the Incidence of Symptomatic Urinary Tract Infections
por: Banakhar, Mai, et al.
Publicado: (2021)

The use of botulinum toxin for the treatment of overactive bladder syndrome
por: Orasanu, Bogdan, et al.
Publicado: (2013)

Onabotulinum toxin A vs. incobotulinum toxin A for the treatment of chronic migraine: a retrospective review
por: Lucchese, Scott, et al.
Publicado: (2023)

Emerging treatments for overactive bladder: clinical potential of botulinum toxins
por: Tincello, Douglas G, et al.
Publicado: (2014)

Real-World Evaluation of the Tolerability to Onabotulinum Toxin A: The RETO Study
por: García-Azorín, David, et al.
Publicado: (2022)

Botulinum Toxin-A Therapy in Pediatric Urology: Indications for the Neurogenic and Non-Neurogenic Neurogenic Bladder
por: Dyer, Lori, et al.
Publicado: (2009)

Botulinum toxin in spinal cord injury patients with neurogenic detrusor overactivity
por: Cho, Young Sam, et al.
Publicado: (2016)

Urodynamic efficacy of fesoterodine for the treatment of neurogenic detrusor overactivity and/or low compliance bladder
por: Kaga, Kanya, et al.
Publicado: (2020)

Neurogenic overactive bladder in spinal cord injury and multiple sclerosis: role of onabotulinumtoxinA
por: Ethans, KD, et al.
Publicado: (2014)

Treating Neurogenic Lower Urinary Tract Dysfunction in Chronic Spinal Cord Injury Patients—When Intravesical Botox Injection or Urethral Botox Injection Are Indicated
por: Chen, Po-Cheng, et al.
Publicado: (2023)

Molecular Mechanism Operating in Animal Models of Neurogenic Detrusor Overactivity: A Systematic Review Focusing on Bladder Dysfunction of Neurogenic Origin
por: Ferreira, Ana, et al.
Publicado: (2023)

Predictive Factors for High Post-void Residual Volume in Older Females After OnabotulinumA Treatment for Severe Overactive Bladder Using a Machine Learning Model
por: Okui, Nobuo, et al.
Publicado: (2023)

The role of botulinum toxin A in treating neurogenic bladder
por: Weckx, Filip, et al.
Publicado: (2016)

The Role of Onabotulinum Toxin Type A in the Management of Chronic Non-migraine Headaches
por: Jia, Cassie, et al.
Publicado: (2019)

Adverse Events of Intravesical OnabotulinumtoxinA Injection between Patients with Overactive Bladder and Interstitial Cystitis—Different Mechanisms of Action of Botox on Bladder Dysfunction?
por: Kuo, Yuh-Chen, et al.
Publicado: (2016)

Further Evidence that Onabotulinum Toxin is a Viable Treatment Option for Pediatric Chronic Migraine Patients
por: Ali, Sameer S, et al.
Publicado: (2019)

The Botulinum Treatment of Neurogenic Detrusor Overactivity: The Double-Face of the Neurotoxin
por: Traini, Chiara, et al.
Publicado: (2019)

Practical Aspects of Botulinum Toxin-A Treatment in Patients With Overactive Bladder Syndrome
por: Liao, Chun-Hou, et al.
Publicado: (2015)

Antimuscarinics for neurogenic overactive bladder in multiple sclerosis: real-life data
por: Andretta, Elena, et al.
Publicado: (2022)

Botulinum toxin-A for the treatment of overactive bladder: UK contributions
por: Seth, JH, et al.
Publicado: (2013)

Bladder diverticuli following injection of onabotulinum toxin A in a patient with multiple sclerosis and autosomal dominant polycystic kidney disease
por: Raza, Syed Imran, et al.
Publicado: (2018)

Nerve sprouting and neurogenic inflammation characterize the neurogenic detrusor overactive bladder of patients no longer responsive to drug therapies
por: Traini, Chiara, et al.
Publicado: (2019)

Robot-assisted laparoscopic radical cystectomy with intracorporeal ileal conduit diversion versus open radical cystectomy with ileal conduit for bladder cancer in an ERAS setup (BORARC): protocol for a single-centre, double-blinded, randomised feasibility study
por: Maibom, Sophia Liff, et al.
Publicado: (2023)

Clinical outcomes of botulinum toxin A management for neurogenic detrusor overactivity: meta-analysis
por: Wu, Shang-Jun, et al.
Publicado: (2019)

Adaptive changes of telocytes in the urinary bladder of patients affected by neurogenic detrusor overactivity
por: Traini, Chiara, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_19j4r9unjbo715bpckn19mepov